Progress in Drug Research

Description

Hepatitis C virus (HCV) was first identified in 1989 as the etiologic agent of non-A, non-B hepatitis [1] and is currently recognized as the leading cause of chronic liver disease worldwide. In contrast to hepatitis B virus infection, in which only about 5% of adult infections become chronic, more than 80% of HCV-infected patients develop chronic hepatitis. Moreover, 20-50% of those persistently infected with HCV will develop liver cirrhosis and hepatocellu­ lar carcinoma (HCC) [2]. It is estimated that there are 10,000 deaths in the USA per year due to chronic liver failure or HCC [3]. In addition, HCV dis­ 25-50% of all liver transplants in US centers, and the ease is responsible for recurrence of HCV infection following liver transplantation is universal [4]. Typically, HCV disease emerges after a 10-20 year period during which symp­ toms, if they exist at all, are mild and non-specific. Although the prevalence varies greatly among different countries, it has been estimated that up to 170 million people (3% of the world's population), are infected with HCV [5]. A recent study in the USA found that 65% of all HCV-infected persons are 30 to 49 years old [6]. Front Matter....Pages i-viii Recent advances in prevention and treatment of hepatitis C virus infections....Pages 1-32 The effects of morphine on cell proliferation....Pages 33-80 Glucosamine and chondroitin sulfates in the treatment of osteoarthritis: a survey....Pages 81-103 Multi-dimensional QSAR in drug research....Pages 105-135 NMR spectroscopy in drug discovery: Tools for combinatorial chemistry, natural products, and metabolism research....Pages 137-211 Prostate cancer and the androgen receptor: Strategies for the development of novel therapeutics....Pages 213-233 Quantitative structure - activity relationships of cardiotonic agents....Pages 235-282 Back Matter....Pages 283-336